-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Ovid Therapeutics, Lowers Price Target to $4

Benzinga·03/24/2025 13:28:39
Listen to the news
BTIG analyst Thomas Shrader maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and lowers the price target from $5 to $4.